Business context and reporting period
The Joint Corp. (NASDAQ: JYNT) filed its Form 10-K for the fiscal year ended December 31, 2023; this is an annual report, not a standalone fourth-quarter report. The company franchises and operates cash-pay chiropractic clinics, does not accept insurance or provide Medicare-covered services, and earns revenue from company-operated clinics, franchise royalties and fees, marketing and software fees. At year-end, it had 935 clinics: 800 franchised and 135 company-owned or managed.
Financial and operating performance
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $117.7 million | $101.3 million |
| Operating income (loss) | $(2.1) million | $0.8 million |
| Net income (loss) | $(9.8) million | $0.6 million |
| Operating cash flow | $14.7 million | $8.2 million |
| Capital expenditures | $5.0 million | $5.9 million |
| Cash and cash equivalents at year-end | $18.2 million | $9.7 million |
- Revenue grew 16.2%, driven by clinic expansion and higher sales at existing clinics. Company-clinic revenue rose 19.0% to $70.7 million; royalty fees increased 11.3% to $29.2 million.
- System-wide sales, a non-GAAP measure that includes franchisee clinic sales, increased 12% to $488.0 million. Patient visits rose to 13.6 million from 12.2 million; comparable sales grew 4% for clinics open at least 13 months, but declined 1% for clinics open 48 months or more.
- Operating expenses and impairment charges pressured reported operating results. The Corporate Clinics segment recorded a $2.5 million operating loss, while Franchise Operations generated $20.3 million of operating income; unallocated corporate expenses were $19.9 million.
- Income before tax was $1.6 million, but income tax expense was $11.4 million, including a $10.9 million valuation allowance against deferred tax assets. The resulting effective tax rate was 695.1% and net loss was $9.8 million.
- Adjusted EBITDA, a company-defined non-GAAP measure, was $12.2 million, up from $11.5 million. It includes adjustments such as stock compensation, impairment, restatement costs and the ERC; it should not be treated as a substitute for GAAP results or operating cash flow.
- Year-end debt under the credit agreement was $2.0 million, at a 7.2% interest rate, and the company reported compliance with its covenants. It repaid the balance on January 17, 2024. Operating lease liabilities were $14.7 million; cash flow from operations covered the year’s investing outflows, which totaled $6.2 million.
Changes, outlook and risks
- The company plans to re-franchise or sell most company-owned or managed clinics, retaining a small number of high-performing locations. Clinics identified for this initiative represented approximately 67% of the corporate clinic portfolio, excluding previously identified sale clinics. Management said the timing and financial impact could not yet be estimated. Two clinic sales for a combined $185,000 were expected to close in Q1 2024; one other clinic sale closed in February 2024.
- Management expects a volatile macroeconomic environment and elevated cost inflation in 2024. It cited labor shortages and wage increases, higher interest rates, and possible weaker discretionary spending. No specific revenue, earnings or margin guidance was provided.
- Management said cash, expected operating cash flows and credit availability should cover anticipated operating and investment needs for at least 12 months, while cautioning that economic or capital-market deterioration could affect liquidity and financing access.
- Unusual items included $3.8 million of ERC income, net of consulting fees, and approximately $1.8 million of noncash impairment losses; the held-for-sale clinic portfolio also had a $0.7 million valuation allowance. ERC eligibility remains subject to IRS audit for five years.
- The company restated prior-period financial statements in September 2023 for errors involving reacquired regional developer rights and VIE transfer pricing. Management reported remediation of prior material weaknesses in internal controls, and the auditor issued unqualified opinions on the financial statements and internal controls.
- Key risks include chiropractor and staff shortages, franchisee performance, regulation of the corporate practice of chiropractic and potential joint-employer liability, competition, clinic lease commitments, cybersecurity and privacy exposure, and the possibility of additional costs or investor confidence impacts related to the restatement. A 2022 breach at a marketing vendor exposed certain patient and employee contact and birth-date information; the company reported no material adverse effect.
Important facts for investors to verify
- Progress, completed transactions, proceeds and any effect on revenue, earnings, cash flow and support costs from the planned clinic re-franchising or sales.
- Whether clinic staffing constraints, wage inflation and lower mature-clinic comparable sales persist, and how these affect clinic-level profitability and franchisee health.
- The basis and sustainability of the $10.9 million deferred-tax valuation allowance, unusually high tax expense, and remaining tax assets and uncertain tax positions.
- Liquidity after the January 2024 debt repayment, continuing operating lease obligations, covenant headroom and reliance on access to financing.
- Continued effectiveness of remediated financial controls, the status of restatement-related matters, and any developments in ERC eligibility, regulatory scrutiny, or cybersecurity incidents.